Franklin Genomic Advancements ETF (HELX)

Assets	$17.81M
Expense Ratio	0.50%
PE Ratio	28.03
Shares Out	550,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	1,807
Open	32.34
Previous Close	32.50
Day's Range	32.34 - 32.43
52-Week Low	23.74
52-Week High	32.62
Beta	1.06
Holdings	67
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

40.83% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	6.02%
Alnylam Pharmaceuticals, Inc.	ALNY	4.78%
Medpace Holdings, Inc.	MEDP	4.59%
Guardant Health, Inc.	GH	4.47%
Insmed Incorporated	INSM	4.39%
Samsung Biologics Co.,Ltd.	207940	3.76%
United Therapeutics Corporation	UTHR	3.34%
Krystal Biotech, Inc.	KRYS	3.24%
Tempus AI, Inc.	TEM	3.20%
Ligand Pharmaceuticals Incorporated	LGND	3.04%

Performance

HELX had a total return of 1.99% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.50%.